The case for & against
Bull & Bear analysis
Bullish
Xeris Biopharma, Inc. (NASDAQ:XERS) is a biopharmaceutical company focused on developing and commercializing innovative injectables for rare diseases, particularly in the space of hormonal therapies. Xeris's flagship products include Recorlev and GVOC, both of which address unmet medical needs in hypercortisolemia and glucagon deficiency. With a robust pipeline, including advancements like XP8121, Xeris is striving to capture significant market share within endocrinology by expanding its commercial capabilities and product offerings.
Bull says
- ↑Q1 2026 net product revenue rose 43% YoY to $82M
- ↑Recorlev sales surged 95%, with $50M in Q1 revenue
- ↑Raised full-year 2026 revenue guidance to $380–$390M
- ↑Initiating Phase III XP8121 trial targeting $1–3B peak sales
- ↑Sales force nearly doubled to expand provider reach
- ↑High earnings yield and strong profitability support upside potential
Bear says
- ↓Negative book-to-price signals potential overvaluation and downside
- ↓Medicare coverage changes cut GVOC prescriptions and revenue
- ↓Elevated leverage heightens financial risk amid market stress
- ↓Volatile stock price may deter risk-averse investors
- ↓Rapid sales force expansion risks operational execution challenges
- ↓Low institutional ownership reflects limited confidence from funds
Investment themes with XERS
Pharmaceuticals↓ -1.67%
Drug development driving global healthcare solutions
JNJ · LLY · RPRX
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-11-2026bullish
Transcript signals
Bull points
- Thank you, Sarah.
- Good morning, everyone, and welcome to Xeris' first quarter financial results conference call.
- Earlier this morning, we issued a press release detailing our first quarter 2026 financial and operating results.
Bear points
- GVOC's performance was slightly below our internal expectations. This was primarily due to Medicare policy and plan changes, which impacted patients' coverage, deductibles, and most importantly, out-of-pocket costs, resulting in a reduction in the number of patients getting their prescriptions filled.
- GVOTE generated net revenue of $20.8 million in the first quarter, flat year over year with soft prescription demand partially offset by favorable net pricing.
- GVOTE's soft start to the year reflects lower total prescription volume, which was primarily driven by a decline in the Medicare channel, resulting from higher than normal out-of-pocket costs, and a reduction in patients getting their prescriptions filled.
Read full transcript analysis ›